CyPass® Supraciliary Microshunt

Text Size

Current Size: 100%

The CyPass® Microshunt is the first FDA-approved MIGS procedure that targets the alternative uveoscleral outflow pathway. This system is independent from traditional trabecular outflow, and a negative pressure gradient between the anterior chamber and the supraciliary space is the principle behind this outflow route. The FDA approved the CyPass® for implantation through a single clear corneal incision in combination with phacoemulsification cataract surgery plus IOL implantation. Following cataract removal and lens implantation, the surgeon introduces the CyPass® Microshunt into the anterior chamber through the same corneal incision utilized for cataract surgery. The device is then inserted into an area called the scleral spur which places the microshunt into the supraciliary space. 

This is an outpatient procedure performed in an ambulatory surgery center. The surgery is usually done under local anesthesia with intravenous sedation. Your doctor will want to examine you in the office the following day and you will be prescribed a regimen of postoperative drops for the next four to six weeks. If the procedure is successful you can expect a decrease in the intraocular pressure and you possibly may come off some of your glaucoma medications. It takes about 6 to 8 weeks before the outcome of the procedure is known.

Frequently Asked Questions

Dilating your pupils with eye drops does cause temporary blurring of vision and increased light sensitivity.  You may be more comfortable having someone accompany you to the office so that he or she can drive you home.  The major effect...

Educational Videos

For additional videos click here